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Abstract
Introduction: Increasing evidence indicates that microRNAs (miRNAs) play a critical role in the pathogenesis of 
inflammatory diseases. The aim of the study was to investigate the expression pattern and function of miRNAs in CD4+ 
T cells from patients with rheumatoid arthritis (RA).
Methods: The expression profile of miRNAs in CD4+ T cells from synovial fluid (SF) and peripheral blood of 33 RA 
patients was determined by microarray assay and validated by qRT-PCR analysis. The correlation between altered 
expression of miRNAs and cytokine levels was determined by linear regression analysis. The role of miR-146a 
overexpression in regulating T cell apoptosis was evaluated by flow cytometry. A genome-wide gene expression 
analysis was further performed to identify miR-146a-regulated genes in T cells.
Results: miRNA expression profile analysis revealed that miR-146a expression was significantly upregulated while miR-
363 and miR-498 were downregulated in CD4+ T cells of RA patients. The level of miR-146a expression was positively 
correlated with levels of tumor necrosis factor-alpha (TNF-α), and in vitro studies showed TNF-α upregulated miR-146a 
expression in T cells. Moreover, miR-146a overexpression was found to suppress Jurkat T cell apoptosis. Finally, 
transcriptome analysis of miR-146a overexpression in T cells identified Fas associated factor 1 (FAF1) as a miR-146a-
regulated gene, which was critically involved in modulating T cell apoptosis.
Conclusions: We have detected increased miR-146a in CD4+ T cells of RA patients and its close correlation with TNF-α 
levels. Our findings that miR-146a overexpression suppresses T cell apoptosis indicate a role of miR-146a in RA 
pathogenesis and provide potential novel therapeutic targets.
Introduction
Rheumatoid arthritis (RA) is a common chronic inflam-
matory disease characterized by radiographic joint
destruction with severe functional deterioration and high
mortality. A hallmark pathological feature of RA is the
infiltration and accumulation of T cells in the synovium
of joint [1]. As the shared epitope in human leukocyte
antigen-DR genes is found in about 80% of RA patients,
dysregulated CD4+ T cell activation and function have
been investigated based on the available evidence of
genetic predisposition [2,3].
T cells isolated from joint tissue and synovial fluid (SF)
show an activated and memory phenotype and appear to
respond poorly to stimulation with mitogen or antigens
in vitro [4,5]. These T cells are unusually resistant to
apoptosis in SF that contains a significant amount of pro-
apoptotic factors such as bioactive FasL, TRAIL and
TNF-α [6,7]. In addition, studies on a murine model of
proteoglycan-induced arthritis also showed that CD4+ T
cells failed to undergo apoptosis [8]. All these findings
from patients and animal models suggest that the inhibi-
tion of T cell death may result in the persistence and
accumulation of T cells in synovium, as well as the accu-
mulation of T cells in the periphery. The long-term sur-
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Page 2 of 12vival of CD4+ T cells has been shown to affect the
behavior of synovial fibroblasts through the cell-to-cell
contact and the secretion of proinflammatory factors
such as Th1 and Th17 cytokines [9,10], ultimately con-
tributing to the maintenance and exacerbation of inflam-
mation in RA [11]. Although elevated levels of anti-
apoptotic proteins such as the Bcl-2 family have been
found in these T cells [12], the possible mechanism
underlying the impaired apoptosis of T cells in RA
remains largely unclear.
MicroRNAs (miRNAs) are about 22 nucleotide (nt)
non-coding RNA that regulate mRNA expression at the
posttranscriptional level for degradation or translational
repression, which have been found to control cell divi-
sion, differentiation and death [13]. To date, thousands of
miRNAs have been identified in mammalian genomes,
and up to 30% of human genes are regulated by them [14].
Recently, miRNAs have been recognized as a novel player
in normal immune function and inflammation [15]. In
particular, T cell-mediated immune responses are associ-
ated with changes in the expression of specific miRNAs.
CD4+ T cells have also been found to express different
miRNAs subsets that are linked to cell differentiation,
maturation, activation and function [16-19]. Notably, a
growing number of reports have revealed that deregula-
tion of miRNA expression contributes to human autoim-
mune diseases including psoriasis and systemic lupus
erythematosus [20,21], in which expression of a set of
altered miRNAs are identified. In RA patients, increased
expression of miR-146a, miR-155, miR-132 and miR-16
have been found in peripheral blood mononuclear cells
(PBMCs) [22]. Recently, analysis of miRNA expression
profile has revealed that miR-223 is overexpressed in
peripheral T cells of RA patients [23].
Moreover, there is evidence that proliferation of fibro-
blast-like synoviocytes is regulated by miR-124a [24]. The
abnormal expression of miR-146 and miR-155 is also
found in the synovium of RA patients, while the expres-
sion of these miRNAs is markedly upregulated in SF after
stimulation with TNF-α and IL-1β [25,26], which indicate
that the inflammatory milieu may alter the miRNAs
expression in joint tissue.
Although a set of altered expression miRNAs have been
identified in synovial tissue or PBMC of patients with RA,
the functions of these dysregulated miRNAs remain
largely unclear. In particular, both the expression profile
and the roles of miRNAs in CD4+ T cells of RA patients
have not been characterized. In this study, we revealed
that miR-146a expression was upregulated in CD4+ T
cells from RA patients, exhibiting a close correlation with
increased levels of TNF-α. Furthermore, we demon-
strated that the increased expression of miR-146a sup-
pressed T cell apoptosis by regulating Fas-associated
factor 1 (FAF1). These findings suggest that miR-146a in
CD4+ T cells may play an important role in RA pathogen-
esis.
Materials and methods
Patients and control samples
All patients in the study who first visited at Rheumatol-
ogy Department of Southwest Hospital fulfilled the
American College of Rheumatology criteria for the classi-
fication of RA. All patients in this study had been diag-
nosed without other complications. The patients had
never been treated with oral or intra-articular corticos-
teroids, disease-modifying antirheumatic drugs
(DMARDs) or other immunosuppressive drugs. How-
ever, nonsteroidal anti-inflammatory drugs and other
symptomatic treatments were given to some patients.
Samples from healthy donors were collected from 12 vol-
unteers, half of which were men and half women. Serum
and peripheral blood samples were collected from RA
patients and healthy donors. SF from RA patients was
collected by routine knee joint paracentesis. At least 10
ml of SF and 20 ml of peripheral blood anticoagulated by
heparin were collected.
All study protocols and consent forms were approved
by the Institutional Medical Ethics Committee of Third
Military Medical University. Written permission was
obtained from all subjects who participated in the study.
Microarray analysis
CD4+ T cells were purified from the SF of two RA
patients and peripheral blood of one healthy donor using
microbeads (MACS, Miltenyi Biotec, Bergisch Gladbach,
Germany). Total RNA of these CD4+ T cells was prepared
using the mirVana miRNA Isolation Kit (Ambion, Austin,
Texas, USA) for miRNA microarray analysis and real-
time RT-PCR assay. Hybridization was carried out using a
miRCURYTM Array microarray kit (Exqion, Vedbaek,
Denmark), which contained 461 mature miRNA probes.
The Affymetrix GeneChip (Human Genome U133 Plus
2.0 Array, Affymetrix, Santa Clara, CA) was used to ana-
lyze over 47,000 transcripts of Jurkat T cells before and
after transfection with FUGW-FF3, FUGW-miR-146a or
FUGW-miR-146a sponge. The expression data and gene
annotations were stored in NCBI's Gene Expression
Omnibus (GEO) database, accession no.
[GEO:GSE21118] and [GEO:GSE21132] [27].
Quantitative RT-PCR analysis
Quantitative RT-PCR assays were performed using a Taq-
Man® MicroRNA Assays kit (Applied Biosystems, Carls-
bad, CA, USA) for the mature miRNA according to
manufacturer's instructions. RUN6B small nuclear RNA
was quantified as a control to normalize differences in
total RNA levels. Specific primers to FAF1 for real-time
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versal Probe Library Assay Design Center (Roche, India-
napolis, Indiana, USA) [28]; β-actin was quantified as the
control. The primer sequences for FAF1 were as follows:
5'-CAGCGGGAGTACAACCTGA-3' (forward) and 5'-
AAGGTCATACACATTTCTCTTTACCTC-3' (reverse).
The quantitative RT-PCR was performed by using
Opticon-2 Detection System (Applied Biosystems, Carls-
bad, CA, USA). All reactions were run in duplicate and
repeated three times. A threshold cycle was determined
in the exponential phases of amplification, and the com-
parative threshold cycle method was calculated with 2ΔΔT
and used to calculate the relative gene expression. The
value of each control sample was set at one and was used
to calculate the fold change in target genes.
Cloning of miR-146a gene and construction of vectors
A 452 bp sequence containing the miR-146a hairpin
(nucleotides 4721752-4722203 of chromosome5-EMBL
reference) was amplified from human genomic DNA by
PCR. The primer sequences for primary miR-146a were
as follows: 5'-AATGCGGCCGCTCAAGAGATCCAC-
CCACATC-3' (forward) and 5'-CCGACGCGTGC-
TACTTGGAACCCTGCTTA-3' (reverse). The miR-
146a-coding genomic DNA fragment was cloned down-
stream from the GFP gene of the lentiviral vector FUGW
by digesting with BsrGI and EcoRI. Similarly, FAF1 cDNA
(Open Biosystems, Huntsville, Alabama, USA) was
cloned into FUGW. The plasmids were verified by
sequencing.
Lentivirus production and transfection
Lentivirus particles derived from HIV were produced by
transient co-transfecting lentiviral expression constructs
into 293FT cells with pFIV-PACK Lentiviral Packaging
Kit (System Biosciences, Mountain View, CA, USA) fol-
lowing Ca3(PO4)2 transfection protocol. The production
of HIV replication incompetent lentiviral particles was
performed by simultaneously delivering lentiviral transfer
vectors and packaging plasmids (pSPAX2 and pMD2.G)
into 293FT cells. Pseudo-viral particles generated by 293
FT cells within 48 hours were centrifuged at 100,000 g for
two hours and frozen at -70°C for later experiments. Jur-
kat T cells were seeded into 24-well plates and lentivirus
was used to transduce at a multiplicity of infection (MOI)
of 10 for 48 hours. Cells were analyzed by FACs and
quantitative RT-PCR.
Cytokines assay
The BD™ Cytometric Bead Array Human Th1/Th2
Cytokine kit (BD Biosciences, San Jose, CA, USA) was
used to quantitatively measure the levels of IL-2, IL-4, IL-
6, IL-10, TNF-α and interferon (IFN)-γ in serum and SF
according to manufacturer's instructions. CD4+ T cells
from healthy donors were transfected with FUGW-FF3
and FUGW-mi-R146a, then stimulated with Phorbol
myristate acetate (PMA) (50 ng/ml) and ionomycin (1 μg/
ml). Levels of IL-2, IL-17A, TNF-α and IFN-γ expression
were detected by intracellular staining. Cytoplasmic
expression of these cytokines was determined in the
green fluorescent protein (GFP+) population by FACs. All
samples were analyzed on a FACS Aria flow cytometer
and all data were analyzed by FlowJo software (BD Biosci-
ences, San Jose, CA, USA).
Cell stimulation
CD4+ T cells were sorted using microbeads (MACS,
Miltenyi Biotec, Bergisch Gladbach, Germany). The
quantity of CD4+ T cells should be at least half million
and the purity should be at least 90%. Jurkat cell line was
purchased from ATCC (Manassas, VA, USA). SF from 10
patients were mixed and centrifuged. The supernatant of
SF mixture was collected. Then Jurkat cells and normal
CD4+ T cells were stimulated by SF diluted to 1:2 or TNF-
α for 48 hours.
Evaluation of cell proliferation and apoptosis
Jurkat T cells transfected with FUGW-FF3 or FUGW-
miR-146a were stimulated with PHA (30 μg/ml) for the
indicated time. Cell proliferation was assayed with a cell
counting kit-8 [29] (CCK-8, Dojindo, Kumamoto, Japan).
Briefly, 10 μl of CCK-8 solution was added to each well of
the plate, and the plate was incubated at 37°C for one
hour. The absorbance was measured at 450 nm as an indi-
cator of cell viability. All experiments were independently
repeated three times. FUGW-FF3, FUGW-miR-146a and
FUGW-miR-146a-FAF1 Jurkat T cells were grown in
RPMI with 3% FBS and stimulated with anti-Fas antibody
(100 ng/ml) for six hours. Cells were stained with
Annexin V and propidium iodide (PI) for flow cytometric
analysis.
Statistical analysis
All data were analyzed by SPSS10.0 software (SPSS, Chi-
cago, IL, USA). Microarray data were analyzed by Cluster
Analysis. All data were represented by mean values ±
standard deviation. P values less than 0.05 were consid-
ered statistically significant. Independent simple T test
was used to compare with different groups. The relation
between miRNA and clinical demographics was analyzed
by Pearson Correlation.
Results
Increased miR-146a expression in CD4+ T cell from SF and 
peripheral blood of RA patients
The expression profiles of miRNAs in CD4+ T cells of SF
from two RA patients were determined by miRNA
microarray analysis. The clinical features and serological
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Compared with normal peripheral blood CD4+ T cells,
pairwise significance analysis of microarray data indi-
cated that the expression levels of eight miRNAs (miR-
363, miR-512-5P, miR-345-MM, miR-146a, miR-146b,
miR-296, miR-133b and miR-150) were increased more
than two-fold by a change in CD4+ T cells of SF from RA
patients whereas eight miRNAs (miR-331, miR-29a, miR-
26a, miR-498, miR-129, let-7a, let-7d and miR-21) were
significantly downregulated (Figure 1a). According to the
results of microarray analysis, we focused on verifying
the expression of those miRNAs whose expression levels
were altered in both RA patients (Figure 1b).
To confirm the microarray data, eight miRNAs with
altered expression levels in both patients (miR-512-5P,
miR-363, miR-345-MM1, miR-146a, miR-146b, miR-150,
miR-498 and miR-129) were analyzed in CD4+ T cells
from 33 patients by quantitative RT-PCR analysis. Both
clinical features and serological parameters of these
patients were shown in Table 2. Compared with CD4+ T
cells from peripheral blood of healthy donors, miR-146a
expression was significantly increased in CD4+ T cells
from both peripheral blood and SF of RA patients, while
miR-498 was only down-regulated in SF T cells from
patients (Figure 1c).
Positive correlation of increased miR-146a expression in T 
cell with elevated TNF-α levels
To determine the possible correlation of these altered
miRNAs with secreted cytokines in RA patients, we mea-
sured the levels of IL-2, IL-4, IL-6, IL-10, IFN-γ and TNF-
α in both SF and serum of RA patients and healthy
donors [Supplemental figure S1 in Additional file 1],
among which the levels of TNF-α were found to be signif-
icantly higher in SF and serum of RA patients than
healthy donors. The linear regression analysis showed
that only miR-146a expression was positively correlated
with the levels of TNF-α in both peripheral blood and SF
of RA patients, but not correlated with the levels of other
cytokines (Figure 2a) and disease activity indexes such as
rheumatoid factor, anti-cyclic citrullinated peptide anti-
body, erythrocyte sedimentation rate, C-reactive protein
and disease activity score of 28 joints (DAS28) scores
(data not shown). Next, Jurkat T cells and normal CD4+ T
cells were stimulated with SF and TNF-α in vitro, and
expression of miR-146a was found to be upregulated in a
dose-dependent fashion (Figure 2b). Moreover, the
expression of miR-498, miR-363 and miR-150 did not
show any correlation with levels of cytokine production
[Supplemental figure S2 in Additional file 2]. Thus, these
data indicate that miR-146a may play a significant role in
inflammation of RA.
Overexpression of miR-146a suppresses T cell apoptosis 
but does not alter cytokine production
To investigate the potential role of miR-146a in T cell
functions, we amplified the coding region of miR-146a
and inserted it into the lentivirus vector FUGW, in which
the ubiquitin promoter drove the expression of GFP and
miR-146a. Moreover, the vector FUGW-FF3 containing
GFP and miR30-shRNA served as a negative control.
Upon transfection with high efficiency, Jurkat T cells
were found to express miR-146a 30 times more than con-
trols (Figure 3a). PHA stimulation, Jurkat T cells with
miR-146a overexpression showed a similar proliferative
response as their controls (Figure 3b). However, miR-
146a-overexpressing Jurkat T cells displayed significantly
reduced apoptosis in culture (Figure 3c). To further verify
the effect of miR-146a overexpression on cytokine pro-
duction in primary T cells, we transfected freshly pre-
pared CD4+ T cells from peripheral blood of healthy
donors and analyzed the profile of cytokine production
after PMA stimulation. Flow cytometric analysis did not
detect any significant alteration in the expression levels of
IFN-γ, TNF-α, IL-2 and IL-17A in normal CD4+ T cells
transfected with miR-146a [Supplemental figure S3 in
Additional file 3].
miR-146a overexpression suppresses T cell apoptosis 
possibly by regulating FAF1 expression
To search for the potential target genes of miR-146a, we
used the miRNA sponge technique employing miRNA
specific decoy targets to suppress endogenous miRNA
activity without affecting its transcription. We con-
structed the miR-146a sponge by inserting two miR-146a
binding sites into the lentivirus vector FUGW with a
reporter gene-eGFP driven by the ubiquitin promoter.
The sponge had an imperfect binding site for miR-146a
seed region, with a bulge at positions 9 to 12, which can
prevent endonucleolytic cleavage (Figure 4a). We trans-
fected the miRNA sponge into Jurkat T cells and com-
pared the gene expression profiles when miR-146a
expression was up- and down-regulated. Together, six
genes were found to be regulated by altered levels of miR-
146a expression (Figure 4b), among which the FAF1
expression was negatively correlated with the levels of
miR-146a as further confirmed by quantitative RT-PCR
analysis (Figure 4c). Next, FAF1 was cloned into lentivi-
rus vector FUGW and plasmid FUGW-miR-146a and
transfected into Jurkat T cells. We further evaluated Fas-
induced apoptosis of Jurkat T cells when transfected with
either miR-146a alone or together with FAF1. It was
found that miR-146a-overexpressing T cells showed sig-
nificantly reduced apoptosis while co-overexpressing
FAF1 abrogated this effect, indicating that miR-146a sup-
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Figure 1 The altered expression profile of miRNAs in CD4+ T cells from SF of RA patients. (a) Compared with normal CD4+ T cells, altered ex-
pression of 16 microRNAs (miRNAs) with fold change (>2) was found in CD4+ T cells of rheumatoid arthritis (RA) by miRNA microarray analysis. (red: 
upregulation; green: downregulation) (b) Expression of eight miRNAs was altered in both RA patients by miRNA microarray analysis. Six of them were 
upregulated and two of them were downregulated. (c) Compared with healthy controls, levels of miRNAs - miR-498, miR-363, miR-146a, miR-150, miR-
512-5P, miR-345-MM1, miR-146b and miR-129 - expression in peripheral blood (PB; n = 20) and synovial fluid (SF; n = 22) of RA patients and PB (n = 
12) of healthy controls were determined by Taqman quantitative RT-PCR analysis. Horizontal bars represent the mean values. Ctl-PB: CD4+ T cells from 
PB of healthy controls; RA-PB: CD4+ T cells from PB of RA patients; RA-SF: CD4+ T cells from SF of RA patients. **P < 0.01, *P < 0.05.
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FAF1 gene in T cells (Figure 5).
Discussion
Increasing evidence indicates that aberrant expression of
miRNAs is implicated in the pathogenesis of autoimmune
diseases. Accumulating data have suggested that the
proper regulation of miRNA expression is important in
the maintenance of normal immune functions and pre-
vention of autoimmunity. A number of miRNAs have
been found to show a tissue-specific pattern during can-
cer development and viral infection. Previous studies
have shown that increased miR-17-92 expression in lym-
phocytes leads to the development of lymphoproliferative
disorder and autoimmune disease in mice [30]. Recently,
upregulated miR-146a has been found in activated pri-
mary T cells and memory T cells [31]. Moreover,
increased miR-146a expression has been detected pri-
marily in PBMC and synoviocytes from RA patients
[22,25]. Although deregulation of miRNA expression has
been observed in human autoimmune diseases, it is still
largely unclear how miRNAs affect autoimmune patho-
genesis in patients. Although a set of altered expression
miRNAs are recently identified in both PBMC and syn-
ovial tissue from RA patients, neither miRNAs expres-
sion profile nor their roles have been fully characterized
in CD4+ T cells of RA patients.
In this study, we have selected the RA patients who did
not have any DMARDs therapy because it is known that
drug treatment can affect expression of miRNAs [32]. We
have found CD4+ T cells from both SF and peripheral
blood of RA patients exhibiting a specific miRNAs
expression profile. Although miR-146a expression was
not found to be associated with the disease activity index
in the current study, our results have shown a significant
positive correlation between miR-146a and TNF-α in
both peripheral blood and SF by dependability statistical
analysis. Furthermore, we have found that miR-146a
expression is upregulated in CD4+ T cells in response to
TNF-α or SF stimulation in vitro. Thus the inflammatory
milieu might alter miR-146a expression in infiltrated T
cells. TNF-α is a critical mediator of the inflammatory
pathway in the rheumatoid joints. As TNF-α inhibition
therapy appears to dramatically reduce markers of
inflammation and slow joint structural damage. Our find-
ings of overexpression of miR-146a in T cells may have
functional implications in eliciting joint inflammation of
RA patients.
In addition to its increasingly recognized function in
modulating innate immunity, miR-146a has been shown
to be involved in Th1/Th2 polarization and regulatory T
cell development [33-36], indicating a potential role for
miR-146a in autoimmune response. Notably, miR-146a
was found to be up-regulated in skin lesions of psoriasis,
PBMC and synovial tissue of RA, whereas it was down-
regulated in PBMC of systemic lupus erythematosus [20-
Table 1: Demographics clinical features of RA patients
Parameter Patient 1 Patient 2
Age (years) 19 48
Sex Female Female
Duration (months) 18 14
RF titer (IU) 74 82.3
ESR (mm/hours) 69 120
CCP titer (IU) 97 85
DAS28 (ESR) score 7.51 6.85
CCP, cyclic citrullinated peptide antibody; DAS28, Disease Activity Score using 28 joint counts; ESR, erythrocyte sedimentation rate; RA, 
rheumatoid arthritis; RF, rheumatoid factor.
Table 2: Demographics and clinical features of RA patients
Parameter Value
Age, mean ± SD years 48 ± 16.5
Sex, male/female 8/33
Duration of symptoms, mean ± 
SD months
58.28 ± 51.84
RF positive, % 84.85%
RF titer, median units(range) 117.4(20-1060)
ESR, mean ± SD mm/hours 67.94 ± 21.19
CCP titer, median units(range) 74.5(15-800)
Stiffness, median 
minutes(range)
76.67 ± 91.31
DAS28 (ESR) score, mean ± SD 6.35 ± 1.45
CCP, cyclic citrullinated peptide antibody; DAS28, Disease 
Activity Score using 28 joint counts; ESR, erythrocyte 
sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid 
factor; SD, standard deviation.
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T cells does not show any affect on cytokine production
in this study, available data on overexpression of miR-
146a in several types of cells of RA suggests that miR-
146a is possibly involved in modulating functions of T
cells and other cells in RA pathogenesis. Although our
current data confirm the increased miR-146a levels in
synovial and peripheral blood CD4+T cells of RA
patients, we were not able to differentiate the expression
pattern of miR-146a levels in various CD4+T cell subpop-
ulations due to the limited numbers of synovial and
peripheral blood CD4+T cells. Further studies are war-
ranted to clarify whether miR-146a expression is
increased in activated T cells or preferentially upregu-
lated in memory T cells of RA patients.
The current understanding of the critical roles of miR-
NAs in regulating cellular functions mainly depends on
the identification of their target genes. TRAF6, a known
target of miR-146a in macrophages and PBMCs, plays a
key role in mediating signals from TNF receptor and IL-1
receptor in innate immunity. The suppressed TRAF6
expression by miR-146a indicated that miR-146a may be
a negative regulator in the TNF-α signal pathway [22,34].
TRAF6 was also identified as a T cell-intrinsic negative
regulator in mice with T cell-specific TRAF6 deletion, in
which signs of hyperactive humoral immunity, including
Figure 2 Positive correlation of miR-146a expression with TNF-α levels in RA patients. (a) A positive correlation was found between miR-146a 
expression and TNF-α levels. Of synovial fluid (SF), 50% increased the expression of miR-146a in Jurkat T cells by 2.39 ± 0.34 fold and in human CD4+ 
T cells by 8.21 ± 1.19 fold (n = 4), respectively. (b) Induction of miR-146a expression stimulated with TNF-α or SF of rheumatoid arthritis (RA) in both 
Jurkat cells and CD4+ T cells. Unstimulated Jurkat T cells or CD4+ T cells were used as controls, respectively. The value of each control sample was set 
at one and further used to calculate the fold change. TNF-α upregulated miR-146a expression in Jurkat T cells and human CD4+ T cells in a dose-de-
pendent fashion.
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autoantibodies [37-39], were observed with similar clini-
cal features of RA.
It has now become clear that certain miRNAs operate
through targeting single genes while others act broadly
through regulating the expression of multiple targets [40].
Up to now, the identification of new targets usually
depends on bioinformatic analysis and experimental
screening. Previously, gene expression analysis has facili-
tated the identification of targets upon overexpressed
plant miRNAs [41]. In contrast to plants, vertebrate miR-
NAs are believed to exert their functions mainly through
translational repression rather than mRNA cleavage [42].
However, it has been recently found that miRNAs can
induce the degradation of mRNAs bearing fully comple-
mentary target sites by similar mechanisms of small-
interfering RNA [43]. Transcriptome analysis can gener-
ate huge datasets with expression levels for all currently
known genes.
Studies on the changes of mRNA expression induced by
miRNAs have been considered as useful methods for
uncovering their new targets and new downstream signal
molecules [44,45], but only the degraded targets can be
identified by transcriptome analysis. As many genes such
as IRAK1, IRAK2, TRAF6, FADD, IRF-5, STAT-1 and
PTC1 have been found to be targets of miR-146a in
human disease [20,31,34,46], the targets and functions of
miR-146a may be different in specific cells. In our experi-
mental system, transcriptome analysis of miR-146a with
up-or down-regulation in Jurkat T cells has not identified
any known targets for miR-146a.
It is plausible to reason that miR-146a may mainly act
through transcriptional repression rather than degrada-
tion of targets by imperfect basepair with the 3'-untrans-
lated region of the targets. FAF1 is known to bind to the
intracellular portion of the apoptosis signal transducing
receptor Fas/Apo-1 and caspase-8 and shows similar
characteristics of Fas-associated death domain protein,
which can enhance Fas-mediated apoptosis [47,48]. We
Figure 3 Overexpression of miR-146a suppresses T cell apoptosis. (a) The expression of miR-146a in Jurkat T cells measured by quantitiative RT-
PCR increased more than 30 fold after transfection with FUGW-miR-146a, but showed no change after transfection with the control vector FUGW-FF3. 
(b) After phytohemagglutinin (PHA) stimulation, Jurkat T cells with miR-146a overexpression showed a similar proliferative response as their controls. 
(c) Upon anti-Fas antibody treatment for six hours, miR-146a-overexpressing Jurkat T cells displayed significantly reduced apoptosis as detected by 
flow cytometry. (d) After six hours of anti-Fas antibody treatment, apoptotic Jurkat T cells were evaluated. The data are derived from three indepen-
dent experiments (mean ± standard deviation). **P < 0.01.
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apoptosis in Jurkat T cells, consistent with previously
reported findings [49]. Interestingly, the ectopic expres-
sion of miR-146a has been found to protect Jurkat T cells
from activation-induced cell death, whereas FADD is
identified as one of its targets [31]. Here, we further dem-
onstrate that overexpression of FAF1 in miR-146a-over-
expressing Jurkat T cells abolished the suppressive effect
of miR-146a on T cell apoptosis. It becomes clear that
activation-induced cell death is mainly mediated via the
Fas/FasL pathway, which plays an important role in the
immunity and induction of peripheral tolerance to self-
antigens. A study by Ryu and colleagues has identified
FAF1 as a member of Fas death-inducing signaling com-
plexes such as FADD [50]. However, our transcriptome
analysis of miR-146a failed to validate FADD as its target.
Currently, it is unclear whether this is due to the detec-
tion limitation of the technique used or the possibility
that miR-146a regulates FAF1 in an FADD-independent
fashion. Interestingly, the expression of two targets of
miR-146, TRAF6 and IL-1 receptor-associated kinase 1,
remains unchanged although miR-146 is upregulated in
PBMC from RA patients [22]. Thus, it remains to be elu-
cidated whether miR-146 exerts its effect on various tar-
gets in a cell-type-dependent manner. Nevertheless, it is
noteworthy that FAF1 does not seem to be a direct target
of miR-146a according to our bioinformatics analysis
[51]. Further studies are needed to identify genes
involved in mediating the effect of miR-146a on FAF1
expression. Dysregulated T cell apoptosis is closely asso-
ciated with autoimmunity diseases, especially RA. Thus,
our findings that miR-146a upregulation in CD4+ T cells
is correlated with increased TNF-α levels may suggest
that miR-146a acts as a critical factor in eliciting and
maintaining the inflammation via suppressing T cell
apoptosis during RA pathogenesis.
Conclusions
In summary, this study revealed that miR-146a expres-
sion was upregulated while miR-363 and miR-498 were
downregulated in CD4+ T cells of RA patients. The level
of miR-146a expression was positively correlated with
levels of TNF-α, and in vitro studies showed TNF-α
upregulated miR-146a expression in T cells. Moreover,
we provided evidence that the increased expression of
miR-146a suppressed T cell apoptosis by regulating FAF1.
Our data indicate that increased miR-146a expression in
Figure 4 Gene expression profiles in Jurkat T cells with up-regulated and down-regulated miR-146a expression. (a) Schematic representation 
of FUGW-miR-146a sponge, which was inserted into lentivirus vector FUGW. (b) Gene expression profiles of Jurkat T cells transfected with FUGW-miR-
146a or FUGW-miR-146a sponge were analyzed by Affymetrix GeneChip. Fas-associated factor 1 (FAF1) was found to be negatively correlated to the 
level of miR-146a. (c) Expression levels of FAF1 were further verified by quantitative RT-PCR, consistent with the results from gene chip analysis. FUGW-
FF3-Jurkat T cells were used as the control. The value of each control sample was set at one and further used to calculate the fold change.
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Figure 5 FAF1 abolishes the suppressive effect of miR-146a on Jurkat T cell apoptosis. (a) Fas-induced apoptosis was evaluated in Jurkat T cells 
transfected with either miR-146a alone or together with Fas-associated factor 1 (FAF1). miR-146a-overexpressing T cells showed significantly reduced 
apoptosis whereas co-overexpressing FAF1 abrogated the effect of miR-146a on T cell apoptosis. (b) After six hours of anti-Fas treatment, apoptotic 
Jurkat T cells were evaluated. The data are derived from three independent experiments (mean ± standard deviation). **P < 0.01.CD4+ T cells is possibly involved in maintaining inflam-
mation during RA pathogenesis.
Although several independent studies have shown
altered expression of miRNAs in PBMC or synovial tissue
of RA patients, our findings that more cell-type-specific
miRNAs were revealed by miRNA expression profile
analysis also represent a distinct advantage. Up to now,
the elucidation of miRNA function represents a veritable
challenge for researchers. It seems that miR-146a regulate
cell function through targeting multiple targets as several
targets of miR-146a were identified. Thus the functions of
miR-146a may be complex and diverse in specific cells or
different stages of inflammation. Further studies on the
role of miR-146a in modulating T cell function will not
only increase our understanding of immune homeostasis,
but also facilitate the identification of new therapeutic
targets for the treatment of patients with RA.
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